pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ahzantive · news · pharmadog
← back to Ahzantive
News mentioning Ahzantive
21
stories
2d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
3d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
6d
Kodiak skyrockets on positive study data for 2 eye drugs
biopharma dive
6d
Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
endpoints
6d
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
biospace
6d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
6d
Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
fiercebiotech
10d
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
Aug 20, 26
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
Aug 17, 26
EyePoint’s bid to compete with Eylea falls flat
endpoints
Aug 17, 26
EyePoint plummets on pivotal data for main drug
biopharma dive
Aug 17, 26
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
Aug 11, 26
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
biospace
Aug 10, 26
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
Jul 30, 26
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
Jul 27, 26
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 6, 26
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
